|
2024-12-17 |
2024-12-16 |
PS
Planned sale
|
O'Neill Vincent
See Remarks
Officer
|
165
-0.8%
0.35
USD 58
|
165
-0.8%
|
0.35
|
USD 58
|
|
|
2024-12-17 |
2024-12-16 |
PS
Planned sale
|
Yocca Frank
Chief Scientific Officer
Officer
|
225
-0.8%
0.35
USD 79
|
225
-0.8%
|
0.35
|
USD 79
|
|
|
2024-12-17 |
2024-12-16 |
PS
Planned sale
|
Yocca Frank
Chief Scientific Officer
Officer
|
205
-0.7%
0.36
USD 73
|
205
-0.7%
|
0.36
|
USD 73
|
|
|
2024-12-17 |
2024-12-16 |
PS
Planned sale
|
Mehta Vimal
CEO and President
Executive Director
Large shareholder
|
2,134
-3.5%
0.36
USD 773
|
2,134
-3.5%
|
0.36
|
USD 773
|
|
|
2024-12-17 |
2024-12-16 |
PS
Planned sale
|
Mehta Vimal
CEO and President
Executive Director
Large shareholder
|
983
-1.6%
0.36
USD 358
|
983
-1.6%
|
0.36
|
USD 358
|
|
|
2024-12-17 |
2024-12-16 |
PS
Planned sale
|
Rodriguez Javier
See Remarks
Officer
|
220
-0.9%
0.36
USD 78
|
220
-0.9%
|
0.36
|
USD 78
|
|
|
2024-12-17 |
2024-12-16 |
PS
Planned sale
|
Rodriguez Javier
See Remarks
Officer
|
210
-0.8%
0.36
USD 75
|
210
-0.8%
|
0.36
|
USD 75
|
|
|
2024-12-17 |
2024-12-16 |
PS
Planned sale
|
Steinhart Richard I
Chief Financial Officer
Officer
|
372
-1.7%
0.36
USD 133
|
372
-1.7%
|
0.36
|
USD 133
|
|
|
2024-12-17 |
2024-12-16 |
PS
Planned sale
|
Steinhart Richard I
Chief Financial Officer
Officer
|
205
-1.0%
0.36
USD 74
|
205
-1.0%
|
0.36
|
USD 74
|
|
|
2024-10-03 |
2024-10-03 |
PS
Planned sale
|
O'Neill Vincent
See Remarks
Officer
|
5,556
-22.1%
0.55
USD 3,056
|
5,556
-22.1%
|
0.55
|
USD 3,056
|
|
|
2024-10-03 |
2024-10-03 |
PS
Planned sale
|
Yocca Frank
Chief Scientific Officer
Officer
|
7,175
-20.2%
0.55
USD 3,946
|
7,175
-20.2%
|
0.55
|
USD 3,946
|
|
|
2024-10-03 |
2024-10-03 |
PS
Planned sale
|
Rodriguez Javier
See Remarks
Officer
|
6,863
-22.4%
0.55
USD 3,775
|
6,863
-22.4%
|
0.55
|
USD 3,775
|
|
|
2024-10-03 |
2024-10-03 |
PS
Planned sale
|
Steinhart Richard I
Chief Financial Officer
Officer
|
7,175
-26.1%
0.55
USD 3,946
|
7,175
-26.1%
|
0.55
|
USD 3,946
|
|
|
2024-10-03 |
2024-10-03 |
PS
Planned sale
|
Wiley Matthew T.
Chief Commercial Officer
Officer
|
6,272
-24.8%
0.55
USD 3,450
|
6,272
-24.8%
|
0.55
|
USD 3,450
|
|
|
2024-09-17 |
2024-09-16 |
PS
Planned sale
|
Mehta Vimal
CEO and President
Executive Director
Large shareholder
|
1,150
-2.2%
0.69
USD 794
|
1,150
-2.2%
|
0.69
|
USD 794
|
|
|
2024-09-17 |
2024-09-16 |
PS
Planned sale
|
Mehta Vimal
CEO and President
Executive Director
Large shareholder
|
832
-1.6%
0.69
USD 573
|
832
-1.6%
|
0.69
|
USD 573
|
|
|
2024-09-17 |
2024-09-16 |
PS
Planned sale
|
Steinhart Richard I
Chief Financial Officer
Officer
|
356
-5.4%
0.69
USD 246
|
356
-5.4%
|
0.69
|
USD 246
|
|
|
2024-09-17 |
2024-09-16 |
PS
Planned sale
|
Rodriguez Javier
See Remarks
Officer
|
345
-3.6%
0.69
USD 238
|
345
-3.6%
|
0.69
|
USD 238
|
|
|
2024-09-17 |
2024-09-16 |
PS
Planned sale
|
Wiley Matthew T.
Chief Commercial Officer
Officer
|
215
-5.1%
0.69
USD 149
|
215
-5.1%
|
0.69
|
USD 149
|
|
|
2024-09-17 |
2024-09-16 |
PS
Planned sale
|
O'Neill Vincent
See Remarks
Officer
|
138
-3.4%
0.69
USD 95
|
138
-3.4%
|
0.69
|
USD 95
|
|
|
2024-09-17 |
2024-09-16 |
PS
Planned sale
|
Yocca Frank
Chief Scientific Officer
Officer
|
355
-2.4%
0.69
USD 245
|
355
-2.4%
|
0.69
|
USD 245
|
|
|
2024-06-18 |
2024-06-17 |
PS
Planned sale
|
Yocca Frank
Chief Scientific Officer
Officer
|
372
-2.7%
1.28
USD 476
|
372
-2.7%
|
1.28
|
USD 476
|
|
|
2024-06-18 |
2024-06-17 |
PS
Planned sale
|
Rodriguez Javier
See Remarks
Officer
|
361
-4.1%
1.26
USD 456
|
361
-4.1%
|
1.26
|
USD 456
|
|
|
2024-06-18 |
2024-06-17 |
PS
Planned sale
|
Steinhart Richard I
Chief Financial Officer
Officer
|
372
-6.4%
1.26
USD 470
|
372
-6.4%
|
1.26
|
USD 470
|
|
|
2024-06-18 |
2024-06-17 |
PS
Planned sale
|
Mehta Vimal
CEO and President
Executive Director
Large shareholder
|
2,134
-4.3%
1.28
USD 2,739
|
2,134
-4.3%
|
1.28
|
USD 2,739
|
|
|
2024-06-18 |
2024-06-17 |
PS
Planned sale
|
Wiley Matthew T.
Chief Commercial Officer
Officer
|
244
-6.5%
1.26
USD 308
|
244
-6.5%
|
1.26
|
USD 308
|
|
|
2024-06-18 |
2024-06-17 |
PS
Planned sale
|
O'Neill Vincent
See Remarks
Officer
|
155
-4.2%
1.29
USD 199
|
155
-4.2%
|
1.29
|
USD 199
|
|
|
2024-06-06 |
2024-06-05 |
S
Sale
|
Mehta Vimal
CEO and President
Executive Director
Large shareholder
|
126,014
-1.6%
1.58
USD 199,619
|
126,014
-1.6%
|
1.58
|
USD 199,619
|
|
|
2024-06-06 |
2024-06-04 |
S
Sale
|
Mehta Vimal
CEO and President
Executive Director
Large shareholder
|
126,014
-1.6%
1.63
USD 205,516
|
126,014
-1.6%
|
1.63
|
USD 205,516
|
|
|
2024-04-08 |
2024-04-04 |
PS
Planned sale
|
Rodriguez Javier
See Remarks
Officer
|
1,012
-11.7%
2.64
USD 2,667
|
1,012
-11.7%
|
2.64
|
USD 2,667
|
|
|
2024-04-08 |
2024-04-04 |
PS
Planned sale
|
Steinhart Richard I
Chief Financial Officer
Officer
|
1,069
-18.3%
2.64
USD 2,817
|
1,069
-18.3%
|
2.64
|
USD 2,817
|
|
|
2024-04-08 |
2024-04-04 |
PS
Planned sale
|
O'Neill Vincent
See Remarks
Officer
|
165
-3.0%
2.62
USD 432
|
165
-3.0%
|
2.62
|
USD 432
|
|
|
2024-04-08 |
2024-04-04 |
PS
Planned sale
|
Mehta Vimal
CEO and President
Executive Director
|
4,439
-9.2%
2.62
USD 11,651
|
4,439
-9.2%
|
2.62
|
USD 11,651
|
|
|
2024-04-08 |
2024-04-04 |
PS
Planned sale
|
Mehta Vimal
CEO and President
Executive Director
|
829
-1.7%
2.62
USD 2,172
|
829
-1.7%
|
2.62
|
USD 2,172
|
|
|
2024-04-08 |
2024-04-04 |
PS
Planned sale
|
Yocca Frank
Chief Scientific Officer
Officer
|
1,067
-7.7%
2.64
USD 2,812
|
1,067
-7.7%
|
2.64
|
USD 2,812
|
|
|
2024-04-08 |
2024-04-04 |
PS
Planned sale
|
Wiley Matthew T.
CHIEF COMMERCIAL OFFICER
Officer
|
1,008
-25.2%
2.64
USD 2,656
|
1,008
-25.2%
|
2.64
|
USD 2,656
|
|
|
2023-06-16 |
2023-06-16 |
PS
Planned sale
|
Mehta Vimal
CEO and President
Executive Director
|
747
-1.8%
21.89
USD 16,352
|
747
-1.8%
|
21.89
|
USD 16,352
|
|
|
2023-06-16 |
2023-06-16 |
PS
Planned sale
|
Mehta Vimal
CEO and President
Executive Director
|
4,266
-9.5%
20.90
USD 89,159
|
4,266
-9.5%
|
20.90
|
USD 89,159
|
|
|
2023-06-16 |
2023-06-16 |
PS
Planned sale
|
Mehta Vimal
CEO and President
Executive Director
|
24,987
-35.7%
20.01
USD 499,990
|
24,987
-35.7%
|
20.01
|
USD 499,990
|
|
|
2023-06-16 |
2023-06-15 |
PS
Planned sale
|
Mehta Vimal
CEO and President
Executive Director
|
8,012
-16.7%
21.90
USD 175,463
|
8,012
-16.7%
|
21.90
|
USD 175,463
|
|
|
2023-06-16 |
2023-06-15 |
PS
Planned sale
|
Mehta Vimal
CEO and President
Executive Director
|
21,988
-31.5%
21.41
USD 470,763
|
21,988
-31.5%
|
21.41
|
USD 470,763
|
|
|
2023-05-24 |
2023-05-22 |
PS
Planned sale
|
Mehta Vimal
CEO and President
Executive Director
|
6,500
-14.8%
25.79
USD 167,641
|
6,500
-14.8%
|
25.79
|
USD 167,641
|
|
|
2023-05-16 |
2023-05-15 |
PS
Planned sale
|
Steinhart Richard I
Chief Financial Officer
Officer
|
5,000
-76.9%
27.17
USD 135,864
|
5,000
-76.9%
|
27.17
|
USD 135,864
|
|
|
2023-05-16 |
2023-05-15 |
PS
Planned sale
|
Rodriguez Javier
See Remarks
Officer
|
1,785
-29.1%
27.32
USD 48,765
|
1,785
-29.1%
|
27.32
|
USD 48,765
|
|
|
2023-04-10 |
2023-04-06 |
PS
Planned sale
|
Nandabalan Krishnan
Non-Executive Director
Large shareholder
|
60,000
-100.0%
17.32
USD 1,039,200
|
60,000
-100.0%
|
17.32
|
USD 1,039,200
|
|
|
2023-03-22 |
2023-03-21 |
PS
Planned sale
|
Mehta Vimal
CEO and President
Executive Director
|
900
-5.4%
20.15
USD 18,135
|
900
-5.4%
|
20.15
|
USD 18,135
|
|
|
2023-03-22 |
2023-03-21 |
PS
Planned sale
|
Mehta Vimal
CEO and President
Executive Director
|
29,100
-63.4%
19.70
USD 573,270
|
29,100
-63.4%
|
19.70
|
USD 573,270
|
|
|
2023-03-22 |
2023-03-20 |
PS
Planned sale
|
Mehta Vimal
CEO and President
Executive Director
|
604
-3.7%
18.88
USD 11,404
|
604
-3.7%
|
18.88
|
USD 11,404
|
|
|
2023-03-22 |
2023-03-20 |
PS
Planned sale
|
Mehta Vimal
CEO and President
Executive Director
|
3,896
-19.1%
18.22
USD 70,985
|
3,896
-19.1%
|
18.22
|
USD 70,985
|
|
|
2023-03-22 |
2023-03-20 |
PS
Planned sale
|
Mehta Vimal
CEO and President
Executive Director
|
5,333
-20.7%
18.86
USD 100,580
|
5,333
-20.7%
|
18.86
|
USD 100,580
|
|
|
2023-03-22 |
2023-03-20 |
PS
Planned sale
|
Mehta Vimal
CEO and President
Executive Director
|
24,667
-48.9%
18.20
USD 448,939
|
24,667
-48.9%
|
18.20
|
USD 448,939
|
|
|
2023-03-16 |
2023-03-15 |
PS
Planned sale
|
Rodriguez Javier
See Remarks
Officer
|
950
-45.6%
19.63
USD 18,644
|
950
-45.6%
|
19.63
|
USD 18,644
|
|
|
2023-03-16 |
2023-03-15 |
PS
Planned sale
|
Yocca Frank
Chief Scientific Officer
Officer
|
985
-9.4%
19.69
USD 19,396
|
985
-9.4%
|
19.69
|
USD 19,396
|
|
|
2023-03-16 |
2023-03-15 |
PS
Planned sale
|
O'Neill Vincent
Chief Medical Officer
Officer
|
845
-40.5%
19.70
USD 16,642
|
845
-40.5%
|
19.70
|
USD 16,642
|
|
|
2023-03-16 |
2023-03-15 |
PS
Planned sale
|
Steinhart Richard I
Chief Financial Officer
Officer
|
2,084
-58.1%
19.50
USD 40,638
|
2,084
-58.1%
|
19.50
|
USD 40,638
|
|
|
2023-01-24 |
2023-01-20 |
PS
Planned sale
|
Yocca Frank
Chief Scientific Officer
Officer
|
50,000
-85.6%
30.00
USD 1,500,000
|
50,000
-85.6%
|
30.00
|
USD 1,500,000
|
|
|
2023-01-24 |
2023-01-20 |
PS
Planned sale
|
O'Neill Vincent
Chief Medical Officer
Officer
|
29,713
-100.0%
30.00
USD 891,390
|
29,713
-100.0%
|
30.00
|
USD 891,390
|
|
|
2023-01-06 |
2023-01-05 |
PS
Planned sale
|
Nandabalan Krishnan
Non-Executive Director
Large shareholder
|
800
-100.0%
22.93
USD 18,344
|
800
-100.0%
|
22.93
|
USD 18,344
|
|
|
2023-01-06 |
2023-01-05 |
PS
Planned sale
|
Nandabalan Krishnan
Non-Executive Director
Large shareholder
|
25,089
-96.9%
22.32
USD 559,986
|
25,089
-96.9%
|
22.32
|
USD 559,986
|
|
|
2023-01-06 |
2023-01-04 |
PS
Planned sale
|
Nandabalan Krishnan
Non-Executive Director
Large shareholder
|
9,821
-100.0%
22.21
USD 218,124
|
9,821
-100.0%
|
22.21
|
USD 218,124
|
|
|
2023-01-06 |
2023-01-04 |
PS
Planned sale
|
Nandabalan Krishnan
Non-Executive Director
Large shareholder
|
24,290
-71.2%
21.59
USD 524,421
|
24,290
-71.2%
|
21.59
|
USD 524,421
|
|
|
2022-12-19 |
2022-12-16 |
PS
Planned sale
|
Mehta Vimal
CEO and President
Executive Director
Large shareholder
|
9,887
-49.8%
19.92
USD 196,949
|
9,887
-49.8%
|
19.92
|
USD 196,949
|
|
|
2022-12-19 |
2022-12-16 |
PS
Planned sale
|
Mehta Vimal
CEO and President
Executive Director
Large shareholder
|
20,113
-50.3%
19.21
USD 386,371
|
20,113
-50.3%
|
19.21
|
USD 386,371
|
|
|
2022-12-19 |
2022-12-15 |
PS
Planned sale
|
Mehta Vimal
CEO and President
Executive Director
Large shareholder
|
7,206
-42.0%
20.19
USD 145,489
|
7,206
-42.0%
|
20.19
|
USD 145,489
|
|
|
2022-12-19 |
2022-12-15 |
PS
Planned sale
|
Mehta Vimal
CEO and President
Executive Director
Large shareholder
|
22,794
-57.0%
19.86
USD 452,689
|
22,794
-57.0%
|
19.86
|
USD 452,689
|
|
|
2022-11-14 |
2022-11-11 |
PS
Planned sale
|
Nandabalan Krishnan
Non-Executive Director
Large shareholder
|
32,550
-100.0%
15.00
USD 488,250
|
32,550
-100.0%
|
15.00
|
USD 488,250
|
|
|
2022-11-14 |
2022-11-10 |
PS
Planned sale
|
Nandabalan Krishnan
Non-Executive Director
Large shareholder
|
27,450
-100.0%
15.00
USD 411,750
|
27,450
-100.0%
|
15.00
|
USD 411,750
|
|
|
2021-06-29 |
2021-06-25 |
S
Sale
|
Mehta Vimal
CEO, President and Secretary
Executive Director
|
473,250
-5.2%
30.83
USD 14,589,493
|
473,250
-5.2%
|
30.83
|
USD 14,589,493
|
|
|
2021-06-29 |
2021-06-25 |
S
Sale
|
Nandabalan Krishnan
Non-Executive Director
|
473,250
-5.2%
30.83
USD 14,589,493
|
473,250
-5.2%
|
30.83
|
USD 14,589,493
|
|
|
2021-06-29 |
2021-06-25 |
S
Sale
|
BioXcel LLC
Large shareholder
|
473,250
-5.2%
30.83
USD 14,589,493
|
473,250
-5.2%
|
30.83
|
USD 14,589,493
|
|
|
2021-06-29 |
2021-06-25 |
S
Sale
|
BioXcel Holdings, Inc.
Large shareholder
|
473,250
-5.2%
30.83
USD 14,589,493
|
473,250
-5.2%
|
30.83
|
USD 14,589,493
|
|
|
2021-03-17 |
2021-03-15 |
PS
Planned sale
|
Yocca Frank
Chief Scientific Officer
Officer
|
630
-1.1%
49.30
USD 31,059
|
630
-1.1%
|
49.30
|
USD 31,059
|
|
|
2021-03-17 |
2021-03-15 |
PS
Planned sale
|
Yocca Frank
Chief Scientific Officer
Officer
|
14,370
-19.6%
48.47
USD 696,514
|
14,370
-19.6%
|
48.47
|
USD 696,514
|
|
|
2021-02-19 |
2021-02-17 |
PS
Planned sale
|
O'Neill Vincent
Chief Medical Officer
Officer
|
600
-100.0%
57.17
USD 34,302
|
600
-100.0%
|
57.17
|
USD 34,302
|
|
|
2021-02-19 |
2021-02-17 |
PS
Planned sale
|
O'Neill Vincent
Chief Medical Officer
Officer
|
9,573
-94.1%
56.60
USD 541,832
|
9,573
-94.1%
|
56.60
|
USD 541,832
|
|
